LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
LTR Pharma has signed a term sheet with Strive Specialties, a United States personalised medicine and 503A pharmacy for ROXUS®. This establishes the pharmacy fulfilment infrastructure required to supply
News update: Leading Australian medical experts are driving public awareness and conversation about the increased severity and prevalence of sexual issues in men aged 65+,
Edison has released a report on LTR Pharma, highlighting the clinical validation of SPONTAN as a fast-acting intranasal treatment for erectile dysfunction and its progression